TRANSGENEX NANOBIOTECH INC has a total of 15 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are TRANSFUSION HEALTH LLC, BIONTEX LAB GMBH and DIAMALT AKTIEN GES.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Biotechnology |
# | Name | Total Patents |
---|---|---|
#1 | Hanna Mazen | 13 |
#2 | Hanna Andrew | 9 |
#3 | Yan Jiyu | 9 |
#4 | Perera Manomi | 9 |
#5 | Mohapatra Shyam | 5 |
#6 | Nair Rajesh | 4 |
#7 | Green Ryan | 4 |
#8 | Mohapatra Subhar | 3 |
#9 | Mohapatra Subhra | 2 |
#10 | Das Mahasweta | 1 |
Publication | Filing date | Title |
---|---|---|
US2020323949A1 | Molecular engineering of a novel ternary complex of actinomycin d for cancer stem cells treatment | |
WO2020205957A1 | Novel ternary molecular complex of tamibarotene for cancer stem cells treatment | |
US2019248800A1 | Novel crystalline forms of mitomycin c for treatment of cancer | |
WO2019160806A2 | Novel crystalline forms of tamibarotene for treatment of cancer | |
US2021053963A1 | Novel crystalline forms of actinomycin d for treatment of cancer | |
CN110177868A | Method for cancer stem cell (CSC) amplification | |
US2010105024A1 | Rapid test including genetic sequence probe |